The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee

NACompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

May 20, 2015

Primary Completion Date

September 30, 2019

Study Completion Date

November 30, 2019

Conditions
Peripheral Arterial DiseaseCardiovascular DiseasePeripheral Vascular Disease
Interventions
OTHER

Paclitaxel administration using the OPC

Trial Locations (17)

28204

Novant Health, Charlotte

29425

Medical University of South Carolina, Charleston

32256

First Coast Cardiovascular Institute, Jacksonville

32504

Coastal Vascular and Interventional, Pensacola

36532

Cardiology Associates, Fairhope

37403

University Surgical Associates, Chattanooga

38305

Kore Cardiovascular Research, Jackson

39401

Hattiesburg Clinic, Hattiesburg

48124

Michigan Outpatient Vascular Institute, Dearborn

48236

St. John Hospital, Detroit

48604

Mid-Michigan Heart & Vascular Center, Saginaw

52807

Vascular Institute of the Midwest, Davenport

70361

Cardiovascular Institute of the South, Houma

75069

North Dallas Research Associates, McKinney

75701

Cardiovascular Associates of East Texas, Tyler

Tyler Cardiovascular Consultants, Tyler

77340

Huntsville Memorial Hospital, Huntsville

Sponsors
All Listed Sponsors
collaborator

Advanced Catheter Therapies, Inc.

INDUSTRY

lead

Horizons International Peripheral Group

OTHER

NCT02464501 - The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee | Biotech Hunter | Biotech Hunter